This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Curnis, F. Articles by Corti, A. Search for Related Content PubMed PubMed Citation Articles by Curnis, F. Articles by Corti, A.

Coupling Tumor Necrosis Factor- with _V Integrin Ligands Improves Its Antineoplastic Activity

¹ Department of Biological and Technological Research and Cancer Immunotherapy and Gene Therapy Program, San Raffaele H. Scientific Institute, Milan, Italy, and
² Consiglio Nazionale delle Ricerche, Istituto di Chimica del Riconoscimento Molecolare, Milan, Italy

Despite the impressive results obtained in animal models, the clinical use of tumor necrosis factor- (TNF) as an anticancer drug is limited by severe toxicity. We have shown previously that targeted delivery of TNF to aminopeptidase N (CD13), a marker of angiogenic vessels, improved the therapeutic index of this cytokine in tumor-bearing mice. To assess whether the vascular-targeting approach could be extended to other markers of tumor blood vessels, in this work, we have fused TNF with the ACDCRGDCFCG peptide, a ligand of _V integrins by recombinant DNA technology. We have found that subnanogram doses of this conjugate are sufficient to induce antitumor effects in tumor-bearing mice when combined with melphalan, a chemotherapeutic drug. Cell adhesion assays and competitive binding experiments with anti-integrin antibodies showed that the Arg-Gly-Asp moiety interacts with cell adhesion receptors, including _Vß₃ integrin, as originally postulated. In addition, ACGDRGDCFCG-mouse TNF conjugate induced cytotoxic effects in standard cytolytic assays, implying that ACGDRGDCFCG-mouse TNF conjugate can also bind TNF receptors and trigger death signals. These results indicate that coupling TNF with _V integrin ligands improves its antineoplastic activity and supports the concept that vascular targeting is a strategy potentially applicable to different endothelial markers, not limited to CD13.

This article has been cited by other articles:

				X. Yuan, X. Lin, G. Manorek, I. Kanatani, L. H. Cheung, M. G. Rosenblum, and S. B. Howell Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors Mol. Cancer Ther., July 1, 2009; 8(7): 1906 - 1915. [Abstract] [Full Text] [PDF]

				E. Tassi, F. Gavazzi, L. Albarello, V. Senyukov, R. Longhi, P. Dellabona, C. Doglioni, M. Braga, V. Di Carlo, and M. P. Protti Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients J. Immunol., November 1, 2008; 181(9): 6595 - 6603. [Abstract] [Full Text] [PDF]

				F. Curnis, A. Sacchi, A. Gasparri, R. Longhi, A. Bachi, C. Doglioni, C. Bordignon, C. Traversari, G.-P. Rizzardi, and A. Corti Isoaspartate-Glycine-Arginine: A New Tumor Vasculature-Targeting Motif Cancer Res., September 1, 2008; 68(17): 7073 - 7082. [Abstract] [Full Text] [PDF]

				H. Wang, K. Chen, W. Cai, Z. Li, L. He, A. Kashefi, and X. Chen Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein Mol. Cancer Ther., May 1, 2008; 7(5): 1044 - 1053. [Abstract] [Full Text] [PDF]

				L. Cao, P. Du, S.-H. Jiang, G.-H. Jin, Q.-L. Huang, and Z.-C. Hua Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature Mol. Cancer Ther., April 1, 2008; 7(4): 851 - 861. [Abstract] [Full Text] [PDF]

				J. Marturano, R. Longhi, V. Russo, and M. P. Protti Endosomal Proteases Influence the Repertoire of MAGE-A3 Epitopes Recognized In vivo by CD4+ T Cells Cancer Res., March 1, 2008; 68(5): 1555 - 1562. [Abstract] [Full Text] [PDF]

				L. Crippa, A. Gasparri, A. Sacchi, E. Ferrero, F. Curnis, and A. Corti Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-{alpha} Cancer Res., February 15, 2008; 68(4): 1154 - 1161. [Abstract] [Full Text] [PDF]

				S. Seresini, M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al. IFN-{gamma} Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions J. Immunol., November 15, 2007; 179(10): 7176 - 7183. [Abstract] [Full Text] [PDF]

				C. Elia, E. Cassol, N. Sidenius, F. Blasi, A. Castagna, G. Poli, and M. Alfano Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion J. Leukoc. Biol., November 1, 2007; 82(5): 1212 - 1220. [Abstract] [Full Text] [PDF]

				S. Zhu, M. Waguespack, S. A. Barker, and S. Li Doxorubicin Directs the Accumulation of Interleukin-12 Induced IFN{gamma} into Tumors for Enhancing STAT1 Dependent Antitumor Effect Clin. Cancer Res., July 15, 2007; 13(14): 4252 - 4260. [Abstract] [Full Text] [PDF]

				F. Curnis, R. Longhi, L. Crippa, A. Cattaneo, E. Dondossola, A. Bachi, and A. Corti Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin J. Biol. Chem., November 24, 2006; 281(47): 36466 - 36476. [Abstract] [Full Text] [PDF]

				S. Bauer, N. Adrian, E. Fischer, S. Kleber, F. Stenner, A. Wadle, N. Fadle, A. Zoellner, R. Bernhardt, A. Knuth, et al. Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins J. Immunol., August 15, 2006; 177(4): 2423 - 2430. [Abstract] [Full Text] [PDF]

				L. Zhang, E. Giraudo, J. A. Hoffman, D. Hanahan, and E. Ruoslahti Lymphatic Zip Codes in Premalignant Lesions and Tumors Cancer Res., June 1, 2006; 66(11): 5696 - 5706. [Abstract] [Full Text] [PDF]

				M. Crosti, R. Longhi, G. Consogno, G. Melloni, P. Zannini, and M. P. Protti Identification of Novel Subdominant Epitopes on the Carcinoembryonic Antigen Recognized by CD4+ T Cells of Lung Cancer Patients. J. Immunol., April 15, 2006; 176(8): 5093 - 5099. [Abstract] [Full Text] [PDF]

				E. Balza, L. Mortara, F. Sassi, S. Monteghirfo, B. Carnemolla, P. Castellani, D. Neri, R. S. Accolla, L. Zardi, and L. Borsi Targeted Delivery of Tumor Necrosis Factor-{alpha} to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin Clin. Cancer Res., April 15, 2006; 12(8): 2575 - 2582. [Abstract] [Full Text] [PDF]

				S. K. Rayala, J. Mascarenhas, R. K. Vadlamudi, and R. Kumar Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol. Cancer Ther., February 1, 2006; 5(2): 230 - 237. [Abstract] [Full Text] [PDF]

				L. Zhang, J. A. Hoffman, and E. Ruoslahti Molecular Profiling of Heart Endothelial Cells Circulation, September 13, 2005; 112(11): 1601 - 1611. [Abstract] [Full Text] [PDF]

				P. Parsons-Wingerter, I. M. Kasman, S. Norberg, A. Magnussen, S. Zanivan, A. Rissone, P. Baluk, C. J. Favre, U. Jeffry, R. Murray, et al. Uniform Overexpression and Rapid Accessibility of {alpha}5{beta}1 Integrin on Blood Vessels in Tumors Am. J. Pathol., July 1, 2005; 167(1): 193 - 211. [Abstract] [Full Text] [PDF]

				E. B. Dickerson, N. Akhtar, H. Steinberg, Z.-Y. Wang, M. J. Lindstrom, M. L. Padilla, R. Auerbach, and S. C. Helfand Enhancement of the Antiangiogenic Activity of Interleukin-12 by Peptide Targeted Delivery of the Cytokine to {alpha}v{beta}3 Integrin Mol. Cancer Res., December 1, 2004; 2(12): 663 - 673. [Abstract] [Full Text] [PDF]

				A. Sacchi, A. Gasparri, F. Curnis, M. Bellone, and A. Corti Crucial Role for Interferon {gamma} in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor {alpha} (NGR-TNF) and Doxorubicin Cancer Res., October 1, 2004; 64(19): 7150 - 7155. [Abstract] [Full Text] [PDF]